Disclosed is a micro-needle including a tip formed using medicine that penetrates into the skin and melts therein; and at least one guide groove each in a stepped shape inward from the outer surface of the tip, and provided to the tip. The micro-needle configured as above may be used to administer a fixed quantity of medicine within a relatively short period of time. Also, since a guide space stepped based on the tip is provided to a base that supports the tip, a large amount of medicine may easily penetrate into the skin.

Provided is a transdermal absorption sheet capable of improving strength against impact at the time of puncture. A transdermal absorption sheet includes a sheet portion and a plurality of needle-like protruding portions arranged on a first principal surface of the sheet portion, in which the sheet portion has a center portion which is a region in which the plurality of needle-like protruding portions are formed, and an outer edge portion which is a region from the center portion to an end portion, and a maximum thickness of a thickness portion of the outer edge portion is larger than an average thickness of the center portion.

Provided are a transdermal absorption sheet capable of achieving control of the dissolution rate and suppression of diffusion of a drug, and a method of producing the same. A transdermal absorption sheet includes a sheet portion, and a plurality of needle-like protruding portions formed by a plurality of frustum portions arranged on the sheet portion and needle portions arranged on the frustum portions, in which at least one of the needle-like protruding portions has a cavity portion extending from the sheet portion to the frustum portion.

The present invention includes compositions and methods of making a modified release pharmaceutical formulation and a method of preparation for the embedding of modified release multi-particulates into a polymeric or wax-like matrix. The modified release multi-particulates comprise an effective amount of a therapeutic compound having a known or desired drug-release profile. Modified release multi-particulates may include a polymeric coat or may be incorporated into particle or core material. The polymer matrix comprises a thermoplastic polymer or lipophilic carrier or a mixture thereof that softens or melts at elevated temperature and allows the distribution of the modified release multi-particulates in the polymer matrix during thermal processing. Formulation compounds and processing conditions are selected in a manner to preserve the controlled release characteristics and/or drug-protective properties of the original modified release multi-particulates.

The present disclosure relates to an ultrasound phantom for a focused ultrasound wave. More specifically, the present invention provides an ultrasound phantom which mimics a body so as to correspond to a speed of sound in the body, in which agarose, sucrose, polydiacetylene vesicle, and distilled water are mixed, and a specific part onto which an ultrasound wave is irradiated by a focused ultrasound transducer is gradually discolored in accordance with a temperature.

The invention provides implantable drug delivery devices comprising a core comprising a polymer (or polymer blend) and one or more drugs or pharmaceutical substances, and an outer shell comprising a polymer (or polymer blend) and one or more porogen materials. The invention reduces burst release of drug. Pharmaceuticals such as triiodothyronine (T3) or ropinirole can be delivered by the devices.

Provided are a production method of a mold, a manufacturing method of a pattern sheet, a production method of an electroform, a production method of a mold using an electroform, and an original. The production method includes: preparing an original having an inclined portion which is formed in an enclosed shape on an outer peripheral portion of a protruding pattern formed at a center portion on a base and gradually increases in thickness from inside toward outside, and a thermoplastic resin sheet; and forming a recessed pattern on the thermoplastic resin sheet by pressing the original which is heated against the thermoplastic resin sheet at a position where a flat surface of the original and a surface of the thermoplastic resin sheet are separated from each other, cooling the original in the state where the original is pressed, and separating the original from the thermoplastic resin sheet.

Multicolored flexible wearables include a first portion having a first flexible polymer forming a toroid and including colorant(s), an exposed first outer surface, an exposed second outer surface, and a recess in the first outer surface not reaching the second outer surface. A second portion formed of a second flexible polymer fills a majority of the recess and includes colorant(s). The first and second flexible polymers have different colors and are permanently bonded together. Precious material particles may be disposed within the first and/or second flexible polymers. One or more of the colorants may have a color matching a color of the precious material particles. One method of bonding the portions includes depositing a liquid second portion into the recess and then curing it. Another method includes depositing a solid second portion into the recess and then curing a liquid layer of polymer between the first portion and second portion.

The present invention relates to the amorphous form of a MALT1 inhibitor, methods of preparation thereof and pharmaceutical compositions comprising this amorphous form.

To provide a microneedle array which includes a sheet and needles, improves transfer of a medicament into the blood, and is capable of achieving high drug efficacy.

Provided is a microneedle array including: a sheet; and a plurality of needles present on the upper surface of the sheet, in which the needles contain a water-soluble polymer and a medicament, the sheet contains a water-soluble polymer, and the administration is performed such that 20 μm≦L2≦L−L1 is satisfied, here, L represents the length of a needle, L1 represents the length of a needle tip region, which contains 90% of the total medicament in the microneedle array, from the needle tip, L2 represents the average remaining length of the needle after administration using the microneedle array, and the unit of L, L1, and L2 is μm.